AKILI, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2291 USD | -3.74% |
|
-0.04% | -52.97% |
| Feb. 29 | Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 29 | Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 7.64M | Sales 2025 * | 11.67M | Capitalization | 18.01M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | -6.33 x |
| Net cash position 2024 * | 66.4M | Net cash position 2025 * | 87.99M | EV / Sales 2025 * | -6 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akili, Inc.
More recommendations
More press releases
| 1 day | -3.74% | ||
| 1 week | -0.04% | ||
| Current month | -20.89% | ||
| 1 month | -15.68% | ||
| 3 months | -24.61% | ||
| 6 months | -51.05% | ||
| Current year | -52.97% |
1 week
0.21
0.25
1 month
0.210.41
Current year
0.190.74
1 year
0.191.67
3 years
0.1937.58
5 years
0.1937.58
10 years
0.1937.58
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Franklin
CEO | Chief Executive Officer | 50 | 22-07-31 |
W. Martucci
FOU | Founder | 42 | 20-11-30 |
Scott H. Kollins
CTO | Chief Tech/Sci/R&D Officer | - | 22-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Jones
BRD | Director/Board Member | 60 | 22-07-31 |
Mary Hentges
BRD | Director/Board Member | 65 | 22-10-24 |
John Spinale
BRD | Director/Board Member | 54 | Feb. 15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 0.2291 | -3.74% | 77,376 |
| 24-04-19 | 0.238 | +2.50% | 51,257 |
| 24-04-18 | 0.2322 | +8.91% | 202,128 |
| 24-04-17 | 0.2132 | -5.16% | 111,127 |
| 24-04-16 | 0.2248 | -1.92% | 51,868 |
End-of-day quote Nasdaq, April 21, 2024
More quotes
Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Companyâs approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.2291
USD
Average target price
0.65
USD
Spread / Average Target
+183.72%
| 1st Jan change | Capi. | |
|---|---|---|
| -52.97% | 18.01M | |
| +8.35% | 209B | |
| +9.41% | 175B | |
| +11.75% | 131B | |
| +19.34% | 99.98B | |
| -0.84% | 61.12B | |
| +15.08% | 52.34B | |
| -2.10% | 46.5B | |
| +0.10% | 39.24B | |
| +11.50% | 38.47B |
- Stock Market
- Equities
- AKLI Stock
